The progressive supranuclear palsy (PSP) therapies market, is anticipated to grow at an annualized r

The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy

London

Roots Analysis has announced the addition of “Progressive Supranuclear Palsy Therapies Market, 2021-2030” report to its list of offerings.

Presently, there is no cure for PSP and the effectiveness of prescribed generic medications and non-drug therapies to improve the quality of life in patients, is limited. The high unmet patient need and rising caregiver burden has inspired several players to focus their efforts on the development of therapies to control the progression of PSP or manage its symptoms. Consequently, multiple orphan designated drugs, currently in phase II of development, are anticipated to enter the market in the next 3-6 years.

To order this 100+ page report, which features 70+ figures, please visit https://www.rootsanalysis.com/reports/progressive-supranuclear-palsy-market.html

Key Market Insights

Currently, over 20 drugs are being developed across preclinical and clinical stages
Majority (50%) of the drug candidates are being evaluated in phase I clinical studies to ease the complexities associated with PSP. Further, owing to their ability to cross the blood-brain barrier, small molecule drugs represent ~70% of the PSP pipeline; this is followed by anti-tau antibodies and antisense oligonucleotides. Since majority of the drugs are small molecules, oral route is the most preferred route.

Leave a Reply